Jared Kaltwasser

The findings mean it may be feasible to use adult systemic lupus nephritis (SLE) trial data to reduce the data needed for pediatric indications.

About 1 in 7 people with systematic onset juvenile idiopathic arthritis (SJIA) will not respond to interleukin-1 or interleukin-6 inhibitors.

New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.

The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found.

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

A new review outlines what is known about cardiovascular disease (CVD) risk in patients with systemic lupus erythematosus (SLE) and how that might affect patient care.

The procedure can be beneficial prior to chemotherapy, but it also has high rates of complications, this new analysis shows.

Most participants were able to complete the assessments at home, and their scores correlated well with in-clinic assessments.

A new case report highlights the potential benefits of risk assessment for women with a family history of autoimmune diseases, such as systemic lupus erythematosus (SLE), who are considering the human papillomavirus (HPV) vaccine.

The new report reverses previous research suggesting that White men who consumed large amounts of gamey meat and rich foods were most at risk.

A new report offers insights from a multidisciplinary team of experts on intrahepatic cholangiocarcinoma (iCCA).

A case report shows the potential of hepatopancreatoduodenectomy for certain patients who might otherwise be thought to have unresectable tumors

Health care providers can help alleviate caregiver burdens by teaching coping strategies, the authors said.

This ratio could be used to better predict disease activity and poor prognosis.

Investigators found significant shifts in diagnosis of and prescriptions for pulmonary hypertension (PH) when exercise right heart catheterization was used.

Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.

The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.

Elevated levels of HER2, VCAM, and TWEAK indicated proteinuria, study authors say of their new findings.

Investigators said they were able to confirm diagnoses of systemic lupus erythematosus (SLE) and thrombotic thrombocytopenic purpura (TTP) because they took a multidisciplinary approach.

New data show the stark contrast between untreated infants with type 1 spinal muscular atrophy (SMA) and those who received risdiplam.

Still, investigators say there are gaps in spinal muscular atrophy (SMA) screening protocol that need to be filled.

New real-world evidence on non–small cell lung cancer (NSCLC) aligns with the results of a 2017 clinical trial.

The combination is approved to treat hepatocellular carcinoma (HCC), but this case report suggests it can also work for combined HCC and cholangiocarcinoma (CHC).

Investigators say recent research into the development of cutaneous lupus erythematosus has created the potential for new therapies.

Investigators say classification based on magnetic resonance imaging can predict a patient’s risk of recurrence for intrahepatic cholangiocarcinoma (iCCA).

More people are eligible for screening, but a new analysis suggests lung cancer disparities are due to more than eligibility status.

The study also found broad tolerability, with 98% of patients remaining on the therapy after 12 months.

Clinical trials and targeted agents do not appear to affect health care–related quality of life, however.

A new case report highlights the difficulties in pinning down spinal muscular atrophy (SMA) when it presents in a mild form.

A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.